ACM
ACAD icon

Ashford Capital Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Ashford Capital Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-43,871
Closed -$1.07M – 113
2021
Q2 		$1.07M Hold
43,871
– – 0.1% 78
2021
Q1 		$1.13M Buy
+43,871
New +$1.93M 0.11% 73

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Ashford Capital Management's ACAD Position: Q3 2021 in Review

Ashford Capital Management sold out of Acadia Pharmaceuticals (ACAD) in Q3 2021, closing a stake of 43,871 shares — an estimated $1.07M sold.

Ashford Capital Management first reported a position in ACAD in Q1 2021 and held it in 2 quarters. The position peaked at $1.13M in Q1 2021. 237 funds tracked by Wall St. Rank hold ACAD as of Q3 2021.

  • Ashford Capital Management reported no remaining Acadia Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Ashford Capital Management sold 43,871 Acadia Pharmaceuticals shares in Q3 2021, an estimated $1.07M.
  • Ashford Capital Management first reported a position in Acadia Pharmaceuticals in Q1 2021 and held it in 2 quarters.
  • Ashford Capital Management's Acadia Pharmaceuticals position peaked at $1.13M in Q1 2021.
  • 237 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2021.

Based on Ashford Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.